Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
September 19, 2014, 08:31:21 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 639375
  • Total Topics: 48534
  • Online Today: 218
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 5
Guests: 153
Total: 158

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: news pro-140?  (Read 1752 times)

0 Members and 1 Guest are viewing this topic.

Offline brazilianman

  • Member
  • Posts: 92
news pro-140?
« on: July 12, 2009, 09:08:06 AM »
no with oneself sign-on the site.
www.progenics.com.

anybody knows publish pro -140?  ???
fail? ???

 ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ??? ???

Offline marius68

  • Member
  • Posts: 27
Re: news pro-140?
« Reply #1 on: November 22, 2009, 10:25:24 PM »
It's kind of old news but still relevant. Only found it now >:(

http://stimuluswatch.org/2.0/awards/view/10814/hiv-1-therapy-with-ccr5-mab-pro-140

PROGENICS PHARMACEUTICALS, INC.
GRANT: $580,717 - NATIONAL INSTITUTES OF HEALTH - AUG. 10, 2009

Award Description: Award Title: HIV-1 Therapy with CCR5 mAb PRO 140 Award Description: PRO 140 is a humanized monoclonal antibody that binds to CCR5, a co-receptor that is the principal molecular portal used by HIV to enter and infect immune system cells. Some strains of HIV use the CXCR4 co-receptor as a portal of entry either exclusively or alternatively to CCR5. Unlike small-molecule CCR5 antagonists, PRO 140 inhibits HIV entry at concentrations that in vitro do not appear to block CCR5's natural activity of directing the migration of immune cells towards sites of inflammation in the body. As a viral-entry inhibitor, PRO 140 is designed to treat HIV by protecting healthy cells from infection. As a monoclonal antibody, PRO 140 may have the potential for a better tolerability profile than many of the existing small-molecule therapies for HIV infection. Clinical studies have established PRO 140 as a potent antiretroviral agent with long-lived activity and an encouraging safety profile. PRO 140 represents a distinct class of CCR5 inhibitor and has the potential to provide the first long-acting, self-administered drug for HIV-1. Successful proof-of-concept studies of PRO 140 in HIV-infected individuals were conducted under parent award U19 066329. Under this ARRA supplement to the parent award, we will conduct further clinical studies with the subcutaneous formulation of PRO 140. The clinical studies are designed to optimize dosing and other conditions prior to initiating the final, pivotal phase of clinical testing. The ARRA funding will accelerate the initiation of the pivotal program and, with success, the ultimate availability to patients of this innovative approach to HIV-1 therapy.

Project Description: We are developing a subcutaneous form of PRO 140 for the treatment of HIV infection. PRO 140 represents a distinct class of CCR5 inhibitor and has the potential to provide the first long-acting, self-administered drug for HIV-1. Previously, under parent award U19 066329, we obtained results from a phase 2 study in which the subcutaneous dosage form of PRO 140 demonstrated potent and highly significant antiviral effects compared to placebo at all doses of active drug examined and was generally well tolerated. Under this ARRA supplement to parent award U19 066329, we have initiated new clinical activities with the subcutaneous form of PRO 140. Successful completion of these activities will represent an important milestone in the development of a potential new treatment option for individuals living with HIV/AIDS.

Jobs Summary: The Associate Director, Clinical Research, Biologics is responsible for Biologics projects. This position represents the Clinical Department on project teams and has direct involvement in writing, conducting, and analyzing clinical studies. This position occasionally provides formal supervision of Clinical Project Managers (CPMs) and takes a leadership role in a matrix clinical team. (Total jobs reported: 1)

Project Status: Less Than 50% Completed

This award's data was last updated on Aug. 10, 2009. Help expand these official descriptions using the wiki below.


 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.